Processa Pharmaceuticals, Inc. Shareholders' Equity
Processa Pharmaceuticals, Inc. (PCSA) had Shareholders' Equity of -$317.34 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent -$317.34K.
- 2026-03-31: Stockholders' Equity Attributable to Parent $2.54M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $5.58M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $5.83M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$317.34K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $2.54M 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $5.58M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $5.83M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $6.11M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $3.53M 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $1.70M 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $3.72M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $6.02M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $8.88M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $4.99M 10-K · filed 2026-03-18 | |
| 2023-09-30 | $7.17M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $9.16M 10-Q · filed 2024-10-30 | |
| 2023-03-31 | $10.14M 10-Q · filed 2024-10-30 | |
| 2022-12-31 | $7.47M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $17.24M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $20.08M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $23.24M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $25.49M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $27.21M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $29.24M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $31.34M 10-Q · filed 2022-11-08 | $31.34M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $22.94M 10-K · filed 2023-03-30 | |
| 2020-09-30 | $5.53M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $6.59M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $7.23M 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $8.01M 10-K · filed 2022-03-30 | |
| 2019-09-30 | $8.67M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $8.50M 10-Q · filed 2020-11-12 | $8.50M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $9.12M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $9.70M 10-K · filed 2021-03-25 | |
| 2018-09-30 | $10.51M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $11.31M 10-Q · filed 2019-11-14 | $11.31M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $7.28M 10-Q · filed 2019-11-14 | |
| 2017-12-31 | $373.16K 10-K · filed 2020-03-06 | $373.16K 10-K · filed 2018-04-16 |
| 2017-09-30 | -$35.05K 10-Q · filed 2017-11-20 | |
| 2017-06-30 | -$2.49M 10-Q · filed 2017-10-04 | |
| 2017-03-31 | -$2.44M 10-Q · filed 2017-10-04 | |
| 2016-12-31 | -$2.27M 10-K/A · filed 2019-04-08 | -$2.35M 10-K · filed 2017-09-25 |
| 2016-09-30 | -$2.25M 10-Q · filed 2017-09-08 | |
| 2016-06-30 | -$2.17M 10-Q · filed 2017-08-30 | |
| 2016-03-31 | -$2.12M 10-Q · filed 2017-08-07 | |
| 2015-12-31 | -$85.70K 10-K · filed 2018-04-16 | -$1.98M 10-K · filed 2017-06-19 |
| 2015-09-30 | -$1.62M 10-Q · filed 2015-12-01 | |
| 2015-06-30 | -$1.32M 10-Q · filed 2015-08-19 | |
| 2015-03-31 | $701.79K 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $1.21M 10-K · filed 2017-06-19 | |
| 2014-09-30 | -$116.77K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $622.99K 10-Q · filed 2014-08-19 | |
| 2014-03-31 | $1.03M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $1.67M 10-K · filed 2015-04-14 | |
| 2013-09-30 | $2.38M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $1.01M 10-Q/A · filed 2013-09-06 | |
| 2012-12-31 | $2.56M 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |